In children, when is L‑methylfolate supplementation indicated and what is the recommended dosing schedule?

L-Methylfolate Supplementation in Children

L-methylfolate is not recommended for routine use in children under 12 years of age, and there is insufficient evidence to support its use in pediatric populations for most indications. 1

Current Evidence and Limitations

The FDA-approved L-methylfolate formulations explicitly state they are not recommended for children under age 12 1. The available guidelines focus almost entirely on folic acid (not L-methylfolate) for neural tube defect prevention in women of childbearing age, not for direct pediatric supplementation 2, 3.

Key Distinction: Folic Acid vs. L-Methylfolate

The robust guideline evidence supports folic acid supplementation (400 mcg daily) for women capable of becoming pregnant to prevent neural tube defects 2. However, this is fundamentally different from giving L-methylfolate directly to children. The guidelines establish important safety thresholds:

• Children ages 1-3 years: Maximum 300 mcg/day of folic acid
• Children ages 4-8 years: Maximum 400 mcg/day of folic acid 3

These upper limits were established due to concerns about masking vitamin B12 deficiency and potential adverse effects including respiratory infections and metabolic disturbances in offspring exposed to high maternal folate levels 3.

Limited Pediatric Research Data

The available pediatric studies are small, retrospective, and focus on psychiatric conditions:

Psychiatric Applications (Off-Label):

• A retrospective study of 146 children/adolescents (ages 7-20) with neuropsychiatric conditions showed L-methylfolate calcium 15 mg/day was well-tolerated, with adverse events occurring in only 10% (primarily sleep impairment and increased anxiety) 4
• However, a 2022 study found no significant improvement in depressive symptoms in children/adolescents with unipolar depression when L-methylfolate was added, regardless of MTHFR genotype or dose 5
• One case report described improvement in autism-related aggression with L-methylfolate in a child with MTHFR C677TT variant 6

Critical Caveat: These studies are retrospective, uncontrolled, and involve severely ill psychiatric populations—they do not establish efficacy or safety for general pediatric use.

Clinical Approach

When L-methylfolate might be considered in children ≥12 years:

1. Documented folate metabolism disorders with confirmed MTHFR polymorphisms causing clinical symptoms
2. Treatment-resistant psychiatric conditions where standard therapies have failed and genetic testing shows relevant variants
3. Always co-administer vitamin B12 (at least 1 mg) to prevent masking B12 deficiency 1
4. Monitor for adverse effects: increased anxiety, sleep disturbances, respiratory symptoms

Dosing (if prescribed off-label for ages ≥12):

• Start with 7.5 mg daily, may increase to 15 mg daily based on response 4
• Ensure total pyridoxine intake remains below 100 mg/day from all sources 1

Do NOT use L-methylfolate in children for:

• General health supplementation
• Neural tube defect prevention (use standard folic acid in women of childbearing age instead)
• Children under 12 years of age

Important Safety Considerations

The evidence shows potential harms from excessive folate exposure in children, including increased insulin resistance when maternal folate is high with concurrent low B12, and possible increased cancer risk at high levels 3. Standard folic acid supplementation at age-appropriate doses remains the evidence-based approach when folate supplementation is truly needed in pediatric populations.

The lack of controlled trials, absence of guideline support, and FDA labeling restrictions make L-methylfolate supplementation in children a decision that should only occur in specific, well-justified clinical scenarios with close monitoring.